MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus

Peter M.K. De Blank, Andrea M. Gross, Srivandana Akshintala, Jaishri O. Blakeley, Gideon Bollag, Ashley Cannon, Eva Dombi, Jason Fangusaro, Bruce D. Gelb, Darren Hargrave, Ae Rang Kim, Laura J. Klesse, Mignon Loh, Staci Martin, Christopher Moertel, Roger Packer, Jonathan M. Payne, Katherine A. Rauen, Jonathan J. Rios, Nathan RobisonElizabeth K. Schorry, Kevin Shannon, David A. Stevenson, Elliot Stieglitz, Nicole J. Ullrich, Karin S. Walsh, Brian D. Weiss, Pamela L. Wolters, Kaleb Yohay, Marielle E. Yohe, Brigitte C. Widemann, Michael J. Fisher

Research output: Contribution to journal › Review article › peer-review

Fingerprint

Dive into the research topics of 'MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry